Rasagiline

Rasagiline is a second-generation propargylamine that selectively and irreversibly inhibits monoamine oxidase type B, the enzyme largely responsible for breaking down dopamine in the brain ^[1]. It is the active R-enantiomer of an earlier racemic compound, and its development as a therapy was advanced by Moussa Youdim and colleagues at the Technion in Israel, with Teva bringing it to market ^[1]. Unlike the older MAO-B inhibitor selegiline, rasagiline is metabolized to a non-amphetamine compound called aminoindan ^[1].

It was approved in the European Union in 2005 and in the United States in 2006 for Parkinson's disease, where it is used as monotherapy in early disease and as an add-on to levodopa in more advanced disease with motor fluctuations ^[1][3]. Clinically it reduces the time when symptoms return between doses, eases early-morning immobility, and can improve non-motor symptoms such as fatigue ^[3]. A large delayed-start trial known as ADAGIO examined whether starting treatment early might slow disease progression; results at the lower dose were consistent with a possible disease-modifying effect, though they were interpreted cautiously because the higher dose did not show the same pattern ^[2].

Beyond blocking MAO-B, the propargylamine structure has been linked in laboratory models to antioxidant and anti-apoptotic actions that have prompted interest in possible neuroprotection ^[1]. Research comparing rasagiline with selegiline has highlighted differences in their downstream effects on dopamine signaling ^[4]. Rasagiline is a prescription-only medicine taken as an oral tablet and is now available generically ^[1].

REGULATORY STATUS. FDA approved 2006 (initial US approval, NDA 021641, AZILECT); EU approval preceded it in 2005. Prescription-only in the US, EU, UK, Canada and Australia. Not a controlled substance and not scheduled under the US Controlled Substances Act. Generic rasagiline mesylate has been widely available since roughly 2017; sixteen distinct tablet labels are currently listed on DailyMed. WADA status could not be verified against a primary source (see notes).

CONTRAINDICATIONS (FDA label). Concomitant meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St John's wort, cyclobenzaprine, or any other MAO inhibitor. These are absolute, not cautions.

WARNINGS. Serotonin syndrome, including fatal cases, when combined with antidepressants; concomitant use with SSRIs, SNRIs, tricyclics, tetracyclics and triazolopyridines is not recommended. A published case report documents serotonin syndrome attributed to rasagiline (PMID 21370275). Hypertensive crisis has been reported at the recommended dose when combined with sympathomimetics. Other labelled warnings: falling asleep during activities of daily living; orthostatic hypotension; exacerbation of levodopa-induced dyskinesia; hallucinations and psychotic-like behaviour; impulse control and compulsive behaviours (gambling, sexual, spending, binge eating); and a neuroleptic-malignant-syndrome-like withdrawal-emergent hyperpyrexia and confusion on abrupt discontinuation or rapid dose reduction.

TYRAMINE. Unlike a non-selective MAOI, rasagiline does not require dietary tyramine restriction at 0.5 or 1 mg/day; the label states this explicitly on the basis of tyramine challenge studies. The residual caution is that foods containing very high tyramine (more than 150 mg) could still cause severe hypertension. Notably, a FAERS disproportionality analysis (PMID 37935702) detected a tyramine-reaction signal for rasagiline and not for selegiline or safinamide, so the reassurance is not absolute in real-world reporting. That same analysis found no amphetamine-effect signal for any of the three MAO-B inhibitors.

COMMON ADVERSE REACTIONS (FDA label, at least 3% above placebo). Monotherapy: flu syndrome, arthralgia, depression, dyspepsia. Adjunct without levodopa: peripheral oedema, fall, arthralgia, cough, insomnia. Adjunct to levodopa: dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, fall, tenosynovitis. Across the early-PD trials, adverse-event rates and dropout rates were not higher than placebo, and dropout was actually lower.

MELANOMA. Melanoma appears in the postmarketing section of the label, and the signal originated during rasagiline's clinical development. Causality is unresolved: Parkinson's disease itself carries an elevated melanoma rate independent of any drug, and a systematic review of 26 studies (PMID 20063399) concluded the association is weak enough that no robust screening recommendation can be made. Periodic dermatological examination is nonetheless commonly advised.

HEPATIC. CYP1A2 is the major metabolic route, so smoking status and CYP1A2 inhibitors both matter. Moderate to severe hepatic impairment is a hard stop.

Rasagiline, a selective MAO-B inhibitor, causes serotonin syndrome when co-administered with selective serotonin reuptake inhibitors (SSRIs); this is a pharmacodynamic interaction where both agents increase synaptic serotonin, causing agitation, rigidity, hyperthermia, and potentially fatal multi-organ failure ^[25]. A documented fatal case involved rasagiline combined sequentially with sertraline and escitalopram, complicated by CYP2D6 intermediate metabolism that increased drug accumulation ^[25].

Unlike the older nonselective MAOIs, rasagiline's selectivity for MAO-B is insufficient to prevent serotonin syndrome with SSRIs, contradicting earlier assumptions about safety ^[25]. Rasagiline is also used safely in combination with certain other therapies including levodopa for Parkinson's disease. What remains unstudied are safe combinations of rasagiline with tricyclic antidepressants or monoamine reuptake inhibitors at lower doses, the time interval required between rasagiline discontinuation and SSRI initiation, and predictive biomarkers for severe serotonin syndrome risk in CYP2D6 variants.

Checking a whole stack? Run it through interactions + stacks.

Rasagiline was developed largely through the work of the pharmacologist Moussa Youdim and colleagues at the Technion, the Israel Institute of Technology, in collaboration with the pharmaceutical company Teva, building on decades of research into monoamine oxidase inhibition for Parkinson's disease. The molecule is a selective, irreversible inhibitor of monoamine oxidase type B whose propargylamine group permanently disables the enzyme that degrades dopamine in the brain.

It was approved in the European Union in 2005 and by the United States Food and Drug Administration in 2006, marketed as Azilect for the treatment of Parkinson's disease both as initial monotherapy and as an add-on to other therapies. Its clinical profile was defined by two major randomized trials, TEMPO and the later ADAGIO study, which together established its symptomatic efficacy and explored the much-debated question of whether it might slow disease progression. Positioned as a more potent successor to the older MAO-B inhibitor selegiline, rasagiline became a widely used option in Parkinson's care.

Rasagiline is well regarded in the treatment of Parkinson's disease for combining genuine symptomatic benefit with a convenient once-daily dose and a favorable tolerability profile. Pooled analyses of the TEMPO and ADAGIO trials confirm that it meaningfully improves motor function and daily activities in early disease, and post-hoc analyses have shown it can hold patients near their baseline motor scores for a year or more.

Clinicians value that it is several times more potent than the older selegiline and that, at recommended doses, it is selective enough that dietary tyramine restriction is generally unnecessary, sparing patients the classic dietary cautions of nonselective MAO inhibitors. It has also attracted scientific interest for the antioxidant and anti-apoptotic properties of its propargylamine structure, which raised the possibility of neuroprotection. In fairness, that disease-modifying promise was not definitively proven in trials, so rasagiline is best appreciated as a reliable, well-tolerated symptomatic therapy with an intriguing but unconfirmed protective hypothesis.